Meeting
2013 ASCO Annual Meeting
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
Authors
Matti S. Aapro
Clinique de Genolier, Genolier, Switzerland
Matti S. Aapro , Giorgia Rossi , Giada Rizzi , Marco Palmas , Steven Grunberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01339260
Citation
J Clin Oncol 31, 2013 (suppl; abstr LBA9514)
DOI
10.1200/jco.2013.31.18_suppl.lba9514
Abstract #
LBA9514
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
First Author: Li Zhang
Poster
2016 ASCO Annual Meeting
Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.
First Author: Kunihiro Matsuzaki
Poster
2014 Palliative and Supportive Care in Oncology Symposium
Evaluation of nausea control with NEPA, a novel oral combination antiemetic.
First Author: Snezana Bosnjak
Poster
2022 ASCO Annual Meeting
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
First Author: Camilla Vieira de Reboucas